Table 3. EORTC QLQ-C30 subscale scores at each assessment.
| Pre-treatment | Immediately after treatment | 6 weeks | 12 months | 24 months | 36 months | |
|---|---|---|---|---|---|---|
| Global QoL | ||||||
| Mean | 67 | 55** | 68 | 70 | 65 | 66 |
| Median | 75 | 50** | 67 | 67 | 67 | 67 |
| (LQ–UQ) | (58–83) | (33–75) | (50–67) | (67–83) | (58–92) | (50–83) |
| EORTC QLQ-C30 functional scales | ||||||
| Physical functioning | ||||||
| Mean | 79 | 75* | 76 | 81 | 80 | 81 |
| Median | 80 | 73* | 80 | 87 | 93 | 93 |
| LQ–UQ | (67–93) | (53–93) | (67–93) | (80–100) | (87–100) | (67–100) |
| Role functioning | ||||||
| Mean | 73 | 55** | 72 | 79 | 80 | 81 |
| Median | 83 | 67** | 67 | 100 | 100 | 100 |
| LQ–UQ | (50–100) | (0–83) | (33–100) | (83–100) | (67–100) | (67–100) |
| Cognitive functioning | ||||||
| Mean | 83 | 76** | 81 | 77 | 73 | 75 |
| Median | 100 | 83** | 83 | 83 | 83 | 83 |
| LQ–UQ | (67–100) | (33–83) | (83–83) | (67–83) | (67–83) | (67–100) |
| Emotional functioning | ||||||
| Mean | 74 | 73 | 73 | 75 | 71 | 72 |
| Median | 75 | 67 | 67 | 83 | 67 | 67 |
| LQ–UQ | (67–83) | (33–75) | (42–75) | (67–83) | (58–83) | (67–100) |
| Social functioning | ||||||
| Mean | 77 | 66* | 75 | 81 | 80 | 81 |
| Median | 83 | 67* | 67 | 100 | 100 | 83 |
| LQ–UQ | (67–100) | (17–100) | (17–83) | (83–100) | (67–100) | (67–100) |
| EORTC QLQ-C30 symptom scales | ||||||
| Fatigue | ||||||
| Mean | 29 | 48** | 36* | 29 | 27 | 22 |
| Median | 22 | 33** | 33* | 11 | 11 | 11 |
| LQ–UQ | (0–22) | (22–67) | (0–56) | (11–33) | (0–22) | (0–33) |
| Nausea | ||||||
| Mean | 9 | 20** | 4 | 8 | 9 | 9 |
| Median | 0 | 17** | 0 | 0 | 0 | 0 |
| LQ–UQ | (0–17) | (0–33) | (0–0) | (0–17) | (0–17) | (0–17) |
| Pain | ||||||
| Mean | 20 | 24 | 18 | 14 | 18 | 20 |
| Median | 17 | 17 | 33 | 0 | 0 | 0 |
| LQ–UQ | (0–17) | (0–67) | (0–33) | (0–17) | (0–17) | (0–17) |
| Dyspnoea | ||||||
| Mean | 14 | 13 | 20 | 14 | 21 | 16 |
| Median | 0 | 0 | 0 | 0 | 0 | 0 |
| LQ–UQ | (0–0) | (0–0) | (0–33) | (0–33) | (0–33) | (0–33) |
| Insomnia | ||||||
| Mean | 35 | 36 | 37 | 27 | 32 | 27 |
| Median | 0 | 33 | 33 | 33 | 33 | 33 |
| LQ–UQ | (0–0) | (0–67) | (33–67) | (0–33) | (0–33) | (0–67) |
| Loss of appetite | ||||||
| Mean | 16 | 36** | 13 | 9 | 9 | 12 |
| Median | 0 | 33** | 0 | 0 | 0 | 0 |
| LQ–UQ | (0–33) | (0–83) | (0–33) | (0–0) | (0–0) | (0–0) |
| Constipation | ||||||
| Mean | 15 | 10 | 9 | 8 | 9 | 12 |
| Median | 0 | 0 | 0 | 0 | 0 | 0 |
| LQ–UQ | (0–0) | (0–0) | (0–0) | (0–0) | (0–0) | (0–0) |
| Diarrhoea | ||||||
| Mean | 10 | 47** | 13* | 13 | 14 | 10 |
| Median | 0 | 67** | 0* | 0 | 0 | 0 |
| LQ–UQ | (0–0) | (33–100) | (0–33) | (0–0) | (0–0) | (0–0) |
| Financial difficulties | ||||||
| Mean | 17 | 20 | 22 | 12 | 14 | 12 |
| Median | 0 | 0 | 0 | 0 | 0 | 0 |
| LQ–UQ | (0–0) | (0–0) | (0–33) | (0–0) | (0–0) | (0–0) |
EORTC=European Organisation for the Research and Treatment of Cancer; LQ–UQ=Lower quartile – upper quartile.
*P<0.01 vs pre-treatment.
**P<0.001 vs pre-treatment.